Literature DB >> 9989540

Drug-induced hypoglycemic coma in 102 diabetic patients.

H Ben-Ami1, P Nagachandran, A Mendelson, Y Edoute.   

Abstract

BACKGROUND: Hypoglycemic coma is a continuous threat for diabetic patients treated with insulin and/or oral hypoglycemic agents; it may be associated with substantial morbidity and mortality.
METHODS: We retrospectively reviewed our clinical experience with drug-induced hypoglycemic coma during a 7-year period.
RESULTS: The study consisted of 102 patients and included 61 females and 41 males. The median age was 72 years. Ninety-two patients suffered from type 2 diabetes mellitus; 10 patients had type 1 diabetes mellitus. The median lowest blood glucose level was 1.77 mmol/L (32 mg/dL). Drug-induced hypoglycemic coma occurred in 99 patients out of the hospital, while 3 patients developed it during hospitalization. Drug-induced hypoglycemic coma occurred in patients undergoing treatment with insulin, glyburide, and combined therapy with insulin and glyburide, insulin and metformin, or glyburide and metformin. Ninety-three patients had at least 1 of the following risk factors: age older than 60 years, renal dysfunction, decreased intake of energy, and infection. Fourteen patients concomitantly received drugs that potentiated hypoglycemia. Forty patients responded to treatment within the first 12 hours, while 62 patients had protracted hypoglycemia of 12 to 72 hours' duration. Morbidity included physical injuries in 7 patients, myocardial ischemia in 2 patients, and stroke in 1 patient. Death occurred in 5 patients.
CONCLUSIONS: Hypoglycemic coma is a serious and not an uncommon problem among elderly patients with diabetes mellitus and treated with insulin and/or oral hypoglycemic drugs. Risk factors contribute substantially to the morbidity and mortality of patients with drug-induced hypoglycemic coma. Enhanced therapeutic monitoring may be warranted when hypoglycemic drugs are administered to an elderly patient with the above predisposing factors and potentiating drugs for hypoglycemia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9989540     DOI: 10.1001/archinte.159.3.281

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  39 in total

1.  Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.

Authors:  A Holstein; A Plaschke; C Hammer; E-H Egberts
Journal:  Eur J Clin Pharmacol       Date:  2003-04-16       Impact factor: 2.953

Review 2.  [New differential therapy of type 2 diabetes].

Authors:  M Schütt; H H Klein
Journal:  Internist (Berl)       Date:  2011-04       Impact factor: 0.743

Review 3.  Can technological solutions for diabetes replace islet cell function?

Authors:  Justin M Gregory; Daniel J Moore
Journal:  Organogenesis       Date:  2011-01-01       Impact factor: 2.500

4.  The risks and benefits of implementing glycemic control guidelines in frail older adults with diabetes mellitus.

Authors:  Sei J Lee; W John Boscardin; Irena Stijacic Cenzer; Elbert S Huang; Kathy Rice-Trumble; Catherine Eng
Journal:  J Am Geriatr Soc       Date:  2011-04-11       Impact factor: 5.562

Review 5.  Causative anti-diabetic drugs and the underlying clinical factors for hypoglycemia in patients with diabetes.

Authors:  Hidekatsu Yanai; Hiroki Adachi; Hisayuki Katsuyama; Sumie Moriyama; Hidetaka Hamasaki; Akahito Sako
Journal:  World J Diabetes       Date:  2015-02-15

Review 6.  An overview of hypoglycemia in the critically ill.

Authors:  Jean-Claude Lacherade; Sophie Jacqueminet; Jean-Charles Preiser
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

7.  Risk factors for recurrent hypoglycemia in hospitalized diabetic patients admitted for severe hypoglycemia.

Authors:  Yen-Yue Lin; Chin-Wang Hsu; Wayne Huey-Herng Sheu; Shi-Jye Chu; Chin-Pyng Wu; Shih-Hung Tsai
Journal:  Yonsei Med J       Date:  2010-05       Impact factor: 2.759

8.  Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis.

Authors:  Carl V Asche; Carrie McAdam-Marx; Laura Shane-McWhorter; Xiaoming Sheng; Craig A Plauschinat
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 9.  The role of sulphonylureas in the management of type 2 diabetes mellitus.

Authors:  Marc Rendell
Journal:  Drugs       Date:  2004       Impact factor: 9.546

10.  Enhanced glucose tolerance by SK4 channel inhibition in pancreatic beta-cells.

Authors:  Martina Düfer; Belinda Gier; Daniela Wolpers; Peter Krippeit-Drews; Peter Ruth; Gisela Drews
Journal:  Diabetes       Date:  2009-04-28       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.